Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2015 May 11;14(7):1521–1531. doi: 10.1158/1535-7163.MCT-15-0100

Figure 3.

Figure 3

In vivo (A-B) and ex vivo (C) biodistribution of ICG/HA-PEI/PEG and ICG/HAPEI/PEG-EGF nanoparticles in SKOV-3WT and SKOV-3TR tumor bearing mice over 1, 2, 4, 6 and 24 h. Quantitative biodistribution studies to assess distribution of siPKM-2 following intravenous dosing of HA-PEI-siPKM-2 as CD44-targeted and dual targeted delivery systems. Quantitative biodistribution studies to assess distribution of siPKM-2 following intravenous dosing of HA-PEI-siPKM-2 as HA-PEI/PEG and dual targeted delivery systems in SKOV-3WT (D) and SKOV-3TR (E) tumor models.